William B. Stilley III
Known title: Chief Executive OfficerCIK: 0001718069
William B. Stilley III's purchase track record
William B. Stilley III has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/29/2021 | ADIL | $55K | -19.5% | -50.8% | -11.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ADIL | ▲ Buy | Grant | 240,800 | $0 | 5/23/2023 | View on chart |
| ADIL | ▼ Sell | Other | 166,667 | $0 | 12/30/2022 | View on chart |
| ADIL | ▲ Buy | Grant | 250,000 | $0 | 2/23/2022 | View on chart |
| ADIL | ▲ Buy | Open Market | 10,600 | $29K | 11/30/2021 | View on chart |
| ADIL | ▲ Buy | Open Market | 10,000 | $26K | 11/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Adial Pharmaceuticals Announces Nasdaq Inducement Grant
Adial Pharmaceuticals disclosed a new inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is relevant as it relates to the company's adherence to exchange listing requirements. The stock currently trades well below its 52-week high, with recent volume spikes observed alongside the announcement.
Adial Pharmaceuticals Announces Nasdaq Inducement Grant. Adial Pharmaceuticals disclosed a new inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is relevant as it relates to the company's adherence to exchange listing requirements. The stock currently trades well below its 52-week high, with recent volume spikes observed alongside the announcement.